CXCR4 and neoplasm: Because intratumoral DCs are necessary for enhanced T cell tumor responses,2, 32 we investigated the effect of the armed oncolytic virotherapy (OVV-CXCR4-A) used alone or in combination with the growth factor FMS-related tyrosine kinase 3 ligand (FLT3L; referred to hereafter as FL) on mobilization of infiltration of CD103+ and CD11b+ DCs to the tumor site and induction of T cell tumor responses.